SCHEMBL15071147

SCHEMBL15071147

Cc1nc2ccc(C(=O)N3CCCCC3)cn2c1-c1cccc(OCC2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ F2RL1 P55085 1/20 0.59
▸ MGLL Q99685 1/20 0.45
▸ KMT2A Q03164 3/20 0.41
▸ TP53 P04637 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ IGF1R P08069 1/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ SLC16A3 O15427 1/20 0.38
▸ SLC16A1 P53985 1/20 0.38
▸ MCTS1 Q9ULC4 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ TGFBR1 P36897 1/20 0.37
▸ ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071134 0.84 F2RL1 (0.57) F2RL1KMT2ATP53MEN1NPC1
SCHEMBL31560 0.81 F2RL1 (0.63) F2RL1KMT2ATP53MEN1NPC1
SCHEMBL15071136 0.80 F2RL1 (0.62) F2RL1KMT2ATP53MEN1NPC1
SCHEMBL15071141 0.80 F2RL1 (0.61) F2RL1KMT2ATP53MEN1NPC1
SCHEMBL15071131 0.80 F2RL1 (0.61) F2RL1KMT2ATP53THRBMEN1
SCHEMBL15071100 0.79 F2RL1 (0.77) F2RL1KMT2AMEN1NPC1RAB9A
SCHEMBL15071144 0.79 F2RL1 (0.60) F2RL1MGLLKMT2AMEN1NPC1
SCHEMBL15071137 0.78 F2RL1 (0.59) F2RL1KMT2AMEN1NPC1RAB9A
SCHEMBL31491 0.78 F2RL1 (0.75) F2RL1KMT2ASLC2A1MEN1
SCHEMBL31568 0.78 F2RL1 (0.56) F2RL1KMT2ATP53MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 — — US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885MGLL 2621/4885KMT2A 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback